Branden Berns is a Partner at Gibson Dunn's San Francisco office, specializing in corporate law with a focus on mergers and acquisitions and complex corporate transactions. Since joining Gibson Dunn in 2015, Branden has represented leading life sciences companies and investors in high-profile deals, including Quidel's $6 billion acquisition of Ortho Clinical Diagnostics and 89bio's $3.5 billion sale to Roche. His expertise extends to various financing transactions, such as IPOs and venture financings. Branden's distinguished career began at Davis Polk in New York, and he holds a Juris Doctor from Columbia Law School, where he was a Harlan Fiske Stone Scholar. He also earned a Bachelor of Science in Economics from Brigham Young University.
LinkedIn
